Get the Stockscreener App
34.35
0.03%
-0.20
Immunovant Inc stock is traded at $34.35, with a volume of 217.82K.
It is down -0.03% in the last 24 hours and up +19.45% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
See More
Previous Close:
$34.15
Open:
$34.95
24h Volume:
217.82K
Relative Volume:
0.13
Market Cap:
$7.04B
Revenue:
-
Net Income/Loss:
$-464.20M
P/E Ratio:
-12.81
EPS:
-2.6823
Net Cash Flow:
$-423.09M
1W Performance:
+29.86%
1M Performance:
+19.45%
6M Performance:
+44.05%
1Y Performance:
+136.10%
1-Day Range:
$33.62
$35.46
1-Week Range:
$30.10
$36.28
52-Week Range:
$13.79
$36.28
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
34.30 | 7.01B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
435.29 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.51 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.09 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.14 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Mkt Perform |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com South Africa
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
Immunovant director Atul Pande sells $192,000 in shares - Investing.com India
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial - Insider Monkey
Immunovant (IMVT) director exercises options, sells 6,000 shares under 10b5-1 plan - Stock Titan
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.67, Implies 66% Upside - TradingView
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT - TechStock²
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
IMVT Stock Jumps As Traders Track Insider Ownership Filing - timothysykes.com
Immunovant rises on IMVT-1402 data in difficult-to-treat RA - BioWorld News
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug - Barron's
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Shares Just Surged 35% – Here’s Why - AskTraders
Immunovant stock hits 52-week high at 30.27 USD By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.08, Implies 64% Upside - TradingView
Immunovant (IMVT) Stock Soars Over 20% Following Breakthrough Rheumatoid Arthritis Data - MEXC
Stifel reiterates Immunovant stock rating on trial results - Investing.com
Immunovant Stock Surges Despite Disappointing Earnings Miss - Benzinga
Stifel reiterates Immunovant stock rating on trial results By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside - TradingView
Crude Oil Down 5%; Lowe's Posts Upbeat EarningsImmunovant (NASDAQ:IMVT), Lowe's Companies (NYSE:LOW) - Benzinga
Immunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial Data - MEXC
These Stocks Are Today's Movers: Nvidia, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More -- Barrons.com - Moomoo
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
May 20 '26 |
Option Exercise |
8.43 |
6,000 |
50,580 |
122,731 |
| Pande Atul | Director |
May 20 '26 |
Sale |
32.00 |
6,000 |
192,000 |
116,731 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):